NALCN is affected predominantly by non-synonymous mutations which enriched in colorectal, gastric, lung, prostate, head, and neck cancers (Weinstein et al., 2013; Martincorena et al., 2017; Rahrmann et al., 2022). Here, NALCN is linked to malignant tumor of neck.